Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Cytotoxic activity of tumor-specific CD8+ T cells Sheila Pellegrino, Kantonsschule Wohlen Antonio Cassarà, Martina Schmittnägel, Miki De Palma lab, ISREC, EPFL Introduction Cancer is one of the leading causes of mortality worldwide, with approximately 8.2 million deaths per year. Cancer is caused by genetic mutations in normal cells, which lead to an uncontrolled growth and, in some cases, to colonization to distant organs. Current available treatments such as surgery, chemotherapy and radiotherapy delay the death of patients but don’t cure the disease, sometimes due to resistance acquired by cancer cells. Immunotherapy is currently among the most promising therapies, giving encouraging results in the clinics. Immunotherapy aims at stimulating one’s own immune system, such as T lymphocytes, in order to fight cancer cells. T lymphocytes are immune cells capable of sensing a variety of signals that can alert them to potentially threatening pathogens as well as cancer cells. Tumor-specific T cells can infiltrate tumors and there encounter tumor-associated antigens presented by specialized antigenpresenting cells (APCs). They subsequently activate, proliferate and eventually kill cancer cells. + In this project, we wanted to investigate how CD8+ T cells get activated and proliferate and how they can kill cancer cells, which express their specific antigen. Figure 1: Activation and proliferation of CD8 T cells. Professional antigen-presenting cells (APCs), principally + dendritic cells, present tumor antigens to CD8 T cells + (cross-presentation) and to CD4 helper T cells. The helper T cells then produce cytokines that stimulate the + expansion and differentiation of the CD8 T cells. Materials and Methods Isolation of CD8+ T cells We isolated CD8+ T cells from the spleen of an OT-I mouse, whose T cells have a transgenic T-cell receptor (TCR) specific to the Ovalbumin protein (OVA), an immunodominant antigen from chicken egg used to track antigen-specific T cells response. We smashed the spleen, lysed the erythrocytes and magnetically labeled CD8+ T cells using Microbeads (Miltenyi Biotec, Cat. no. 130-049-401). The cell suspension was loaded onto a 1 autoMACS Pro Separator Machine, which separates the CD8- cells fraction from the CD8+ cells fraction. Activation and proliferation of CD8+ T cells We seeded 200’000 CD8+ T cells/well in a round-bottom 96-well plate and added the OVA peptide at a final concentration of 250 µg/ml. We stained some T cells using the CellTrace Violet Cell Proliferation Kit (Invitrogen, Cat. no. C34557), to assess their proliferation. We analyzed them by flow cytometry at day 3. The rest of T cells was used for the killing assay at day 2. LDH colorimetric assay 24h before the assay, we seeded 20’000 cancer cells in a flat-bottom 96-well plate and let them adhere overnight. The day after, we added pre-activated T cells at different ratios (20’000, 40’000 or 60’000) and co-culture them for 20 hours in a final volume of 100 µl. We measured the level of cytotoxicity with the Pierce LDH Cytotoxicity Assay Kit (Thermo Scientific, Cat. no. 88953). We transferred 50 µl of each sample medium to a new 96-well plate, added 50 µl of substrate (Lactate), incubated for 30 min at room temperature and, finally, measured the absorbance at 490 nm. Figure 2: LDH colorimetric assay. Time laps microscopy We co-cultured 20’000 cancer cells with 40’000 pre-activated CD8+ T cells in phenol-free medium. We added propidium iodide (PI) to the medium, which stains dead cells. We let the co-culture for 4h and took an image every 5 min with a time-laps microscope. 2 Results CD8+ T cells proliferation Figure 2 shows how many rounds of proliferation our CD8+ T cells underwent during 3 days. The CD8+ T cells were stained at day 0 with a dye-tracer, which dilutes at each round of cell division. The more a cell divides, the less intense is his tracer. The x-axis indicates the intensity of tracer, while the y-axis is a physical parameter. Our CD8+ T cells proliferated six times, most of them being in their sixth division. + Figure 3: Proliferation of OT-I CD8 T cells. Killing assay In order to check the cytotoxic effect of activated OVA-specific CD8+ T cells, we made a coculture of CD8+ T cells and OVA positive or negative cancer cells, at different ratios. As cancer cells, we chose a murine colorectal cancer cell line (MC38, MC38-OVA) and a murine melanoma cell line (B16, B16-OVA). We assessed the killing activity with two different methods: a LDH colorimetric assay and time-laps microscopy. LDH (Lactate dehydrogenase) is a cytosolic enzyme, which is released in the cell culture medium upon plasma membrane damage. Extracellular LDH activity in the medium can be quantified using a plate-reading spectrophotometer and is indicative of cellular cytotoxicity. The percentage of cytotoxicity has been calculated as follows: As expected, we observed an increased level of cytotoxicity in OVA-expressing cancer cells (MC38-OVA and B16-OVA) compared to the respective wild-type cell lines (MC38 and B16). Moreover the killing was more efficient with increased T cell : Cancer cell ratio in MC38-OVA and B16-OVA, but also at a smaller extent in MC38 and B16. 3 % Cytotoxycity after 20h 80 B16 B16-OVA 60 40 20 0 1:1 1:2 1:3 Cancer cells : CD8+ T cells % Cytotoxycity after 20h 80 MC38 MC38-OVA 60 40 20 0 1:1 1:2 1:3 Cancer cells : CD8+ T cells Figure 4: Percentages of cellular cytotoxicity after 20h incubation with activated CD8+ T cells We used also a time-laps microscopy to see the killing activity over a period of time (4h), to track the dynamic movement of T cells and to see if some cancer cells were killed (became red). We could see that the cancer cells are in general very static, while the T cells move a lot to scan for MHC-peptide complexes specific to their TCR. We indeed observed that the CD8+ T cells associated more with the cancer cells that express the OVA compared to the ones without. However, we couldn’t see any cancer cells turning red, probably because the time was not sufficient. 4 Figure 5: Time-lapse microscopy. Cancer cells were co-cultured with activated CD8+ T cells for 4h and dead cells were stained with propidium iodide (red). Conclusions Our CD8+ T cells were able to get activated and proliferate 6 times after 3 days of culture with the OVA peptide. In general, in order for a naïve T cell to become active and proliferate, it needs an antigen-presenting cell that present its specific antigen and a T-helper cell. However, in our experiment the CD8+ T cells proliferated just with the addition of the OVAprotein, because our isolation was not 100% pure and thus a small number of contaminants, such as dendritic cells or T-helper cells, remained and were sufficient to activate CD8+ T cells. The LDH colorimetric assay worked according to our expectations. It shows that activated T cells kill only the cancer cells that express their specific antigen. However, we also observed a small increased cytotoxicity in the wild-type cancer cells (MC38, B16) with an increased T cell: cancer cell ratio. This can be explained as unspecific killing. The time-laps microscopy worked, but the protocol can be optimized. We were not able to see any apoptotic cancer cell, for two possible reasons. The 4h time point might have been 5 too short to see the killing (indeed, in the LDH colorimetric assay the co-culture lasted 20h), but enough to see the attacking action. Also, there might have been too many T cells, resulting in a total coverage of the cancer cell surface, making it impossible for us to recognize some red colored cancer cells. Acknowledgements I would like to thank the organization "Schweizer Jugend Forscht" and Alice Emery-Goodman for this very special and enriching week full of new experiences and information. Also, for giving us students the opportunity to undergo such a project. I would also thank Miki De Palma, for having accepted me in his lab, my supervisor Antonio Cassarà for guiding me through this project and all the interesting experiments. In addition, I would practically thank most of the people, Martina, Jean-Baptiste, Maria, who work in that lab for their help from any kind. References 1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr (link is external), accessed December 2013. 2. Urry, Lisa A., et al. Campbell biology. Boston: Pearson, 2011. 3. Restifo, Nicholas P., Mark E. Dudley, and Steven A. Rosenberg. "Adoptive immunotherapy for cancer: harnessing the T cell response." Nature Reviews Immunology 12.4 (2012): 269-281. 4. Abbas, Abul K., Andrew HH Lichtman, and Shiv Pillai. Basic immunology: functions and disorders of the immune system. Elsevier Health Sciences, 2012. 6